Evidence map›Paper›PMID 37160922›Full record

ArticleScientific reports2023

Distinct oncogenic phenotypes in hematopoietic specific deletions of Trp53.

Jayanth Kumar Palanichamy, Tiffany M Tran, Jennifer K King, Sol Katzman, Alexander J Ritter, Gunjan Sharma, Christine Tso, Jorge R Contreras, Thilini R Fernando, Jeremy R Sanford and 1 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Genetic Mouse Models of Lymphomas.Methods in molecular biology (Clifton, N.J.) · 2025
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 2 countries.

Jayanth Kumar PalanichamyDepartment of Biochemistry, All India Institute of Medical Sciences, New Delhi, India.
Tiffany M TranDepartment of Pathology and Laboratory Medicine, UCLA, Los Angeles, USA.
Jennifer K KingDepartment of Medicine, UCLA, Los Angeles, USA.
Sol KatzmanCenter for Biomolecular Science & Engineering, UCSC, Santa Cruz, USA.
Alexander J RitterDepartment of Molecular, Cell and Developmental Biology and Center for Molecular Biology of RNA, UCSC, Santa Cruz, USA.
Gunjan SharmaDepartment of Biochemistry, All India Institute of Medical Sciences, New Delhi, India.
Christine TsoDepartment of Pathology and Laboratory Medicine, UCLA, Los Angeles, USA.
Jorge R ContrerasDepartment of Pathology and Laboratory Medicine, UCLA, Los Angeles, USA.
Thilini R FernandoDepartment of Pathology and Laboratory Medicine, UCLA, Los Angeles, USA.
Jeremy R SanfordDepartment of Molecular, Cell and Developmental Biology and Center for Molecular Biology of RNA, UCSC, Santa Cruz, USA.
Dinesh S RaoDepartment of Pathology and Laboratory Medicine, UCLA, Los Angeles, USA. drao@mednet.ucla.edu.
University of California, Santa Cruz · USAll India Institute of Medical Sciences · INUniversity of California, Los Angeles · US

Funding

Women's CancersP30CA016042 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Samuel Wheeler French · 1985 to 2026
$134.5M
Virology CoreP30AI028697 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI JAMIESON-KARAVODIN, BETH DEIRDRE · 1991 to 2018
$39.9M
TUMOR CELL SURFACES AND CHROMOSOMEST32CA009056 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Gay M Crooks, David A. Nathanson · 1985 to 2026
$10.5M
UCLA Tumor Immunology Training ProgramT32CA009120 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Steven M. Dubinett, MICHAEL A TEITELL · 1985 to 2026
$10.3M
Protein-RNA interactions in cancerR01CA264986 · NCI · UNIVERSITY OF CALIFORNIA SANTA CRUZ · PI Dinesh S. Rao, Jeremy Robert Sanford · 2021 to 2026
$3.7M
Regulation of mRNA FateR35GM130361 · NIGMS · UNIVERSITY OF CALIFORNIA SANTA CRUZ · PI Jeremy Robert Sanford · 2019 to 2026
$3.1M
Characterizing tumor suppressive functions of microRNAs in B-cell neoplasiaR01CA166450 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI RAO, DINESH S · 2013 to 2017
$2.5M
Regulation of mRNA isoform fateR01GM109146 · NIGMS · UNIVERSITY OF CALIFORNIA SANTA CRUZ · PI SANFORD, JEREMY ROBERT · 2014 to 2017
$1.2M
The Role of MicroRNA-146a in B Cell Function and AutoimmunityK08AR072787 · NIAMS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI KING, JENNIFER K · 2018 to 2022
$886k
NCI NIH HHS P30 CA016042NCI NIH HHS R01 CA166450NCI NIH HHS R01 CA264986NCI NIH HHS T32 CA009056NCI NIH HHS T32 CA009120NIAID NIH HHS P30 AI028697NIAMS NIH HHS K08 AR072787NIGMS NIH HHS R01 GM109146NIGMS NIH HHS R35 GM130361NIH HHS K08AR072787NIH HHS R01CA264986NIH HHS T32 CA009056NIH HHS T32CA009120Wellcome Trust
6 · The paper itself

Abstract

Loss of function in the tumor suppressor gene TP53 is the most common alteration seen in human cancer. In mice, P53 deletion in all cells leads predominantly to the development of T-cell lymphomas, followed by B-cell lymphomas, sarcomas and teratomas. In order to dissect the role of P53 in the hematopoietic system, we generated and analyzed two different mouse models deficient for P53. A pan-hematopoietic P53 deletion mouse was created using Vav1-Cre based deletion; and a B-cell-specific deletion mouse was created using a CD19-Cre based deletion. The Vav1-P53CKO mice predominantly developed T-cell malignancies in younger mice, and myeloid malignancies in older mice. In T-cell malignancies, there was accelerated thymic cell maturation with overexpression of Notch1 and its downstream effectors. CD19-P53CKO mice developed marginal zone expansion in the spleen, followed by marginal zone lymphoma, some of which progressed to diffuse large B-cell lymphomas. Interestingly, marginal zone and diffuse large B-cell lymphomas had a unique gene expression signature characterized by activation of the PI3K pathway, compared with wild type marginal zone or follicular cells of the spleen. This study demonstrates lineage specific P53 deletion leading to distinct phenotypes secondary to unique gene expression programs set in motion.

Indexed as

Hematopoietic SystemLymphoma, Large B-Cell, DiffuseAdaptor Proteins, Signal TransducingAnimalsAntigens, CD19HumansMicePhosphatidylinositol 3-KinasesSpleenTumor Suppressor Protein p53Adaptor Proteins, Signal TransducingAntigens, CD19Phosphatidylinositol 3-KinasesTumor Suppressor Protein p53

Identifiers

PMID37160922
PMCPMC10169790
OpenAlexW4376131063

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.